• Helix BioPharma Corp., of Aurora, Ontario, closed a private placement of 4.53 million units at $2.43 per unit, with expected proceeds of $11 million. Each unit consists of one common share and one common share purchase warrant, with each common share purchase warrant entitling the holder to purchase, subject to adjustment, one common share of Helix at a price of $3.40 for up to three years after the closing date of the private placement. Net proceeds after expenses are expected to be about $9.5 million and will be used for working capital, primarily to support Helix's expanding clinical trial initiatives.